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Background: Seasonal influenza is one of the most significant infectious diseases in Germany; epidemic outbreaks
occur every winter and cause substantial morbidity and mortality. However, published data from Germany on the
current economic burden of influenza and the costs per episode are lacking.
Methods: A retrospective database analysis was conducted using a longitudinal electronic medical records database
(IMS Disease Analyzer). Patients with influenza, diagnosed by German office-based physicians using ICD-10 J09-11
(International Classification of Diseases, 10th revision), who were observable in the database from 12 months before the
index (diagnosis) date until 1 month afterwards, were included. The selection window, defined to cover two
influenza seasons, was May 2010 to April 2012. Direct and indirect costs were evaluated from payer, patient and
societal perspectives. Published unit costs and tariffs from Germany (2012) were used for the analysis.
Results: A total of 21,039 influenza-attributable episodes in 17,836 adults, managed by primary care physicians
(PCP) and 7,107 episodes in 6,288 children, managed by pediatricians, were eligible for analysis. The mean
(±Standard Deviation (SD)) age of the adults with at least one episode was 46 (±18) years and 7 (±4) years in the
children. The presence of clinical risk factors was documented for 39 % episodes in adults and 24 % episodes in
children, with the most common being cardiovascular diseases in adults (29 %) and chronic respiratory diseases in
children (23 %). Complications and severe symptoms accompanied the influenza-attributable episode (adults:
37 %, children: 54 %), bronchitis (adults: 16 %, children: 19 %) and acute upper respiratory infection (adults: 15 %,
children: 21 %) being the most frequent. From a societal perspective, the total average mean cost (±SD) per
episode was €514 (±609) in adults, where work days lost were the main cost driver (82 %), and €105 (±224) in
children. Complications and severe symptoms increased the cost per episode versus episodes without by 1.7 times
in adults (€684 (±713) vs. €413 (±510)) and nearly 3 times in children (€149 (±278) vs. €55 (±116)).
Conclusions: Based on a large patient sample derived from representative PCP and pediatricians panels, our
results demonstrate that seasonal influenza is associated with substantial clinical and economic burden in Germany.
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Influenza is an acute viral infection characterized by a
range of symptoms, including sudden onset of high fever,
cough, sore throat, headache, muscle and joint pain, severe
malaise and a runny nose. Despite putting a high burden
on patients and being of high socio-economic relevance to
society, influenza is often regarded as an unproblematic
and self-limiting disease, though, epidemic outbreaks, af-
fecting all age groups, occur every winter and cause
substantial morbidity and mortality. The World Health
Organization (WHO) estimates that every year, 3–5 mil-
lion severe cases and 250,000–500,000 deaths are caused
by the influenza virus worldwide [1].
Influenza imposes a considerable economic burden as
well. In Italy, the reported cost of seasonal influenza
epidemics (1999–2008) ranged from €0.3 to €2.7 billion;
the yearly average was €1.4 billion [2]. In Germany, the
sole cost of the 1996 influenza epidemic was estimated
at €2.6 billion (DM 5 billion) including direct costs, due
to hospitalization, outpatient care and medication, as well
as indirect costs, due to loss of work force productivity
and absenteeism from work [3]. According to an analysis
from the United States (US), the direct costs relating to
hospitalization and treatment are twice as high when
complications occur [4]. Groups at high risk of complica-
tions are the elderly, infants and patients with chronic
illnesses [1]. Indirect costs arising during an influenza sea-
son were found to make up 80–90 % of the total costs in
Germany and France [3, 5].
Vaccination has been shown to be the most cost-
effective intervention in preventing infection and subse-
quently reducing the associated financial burden [6, 7].
Safe and effective influenza vaccines prevent 44–73 % of
influenza symptoms among healthy adults [8] and reduce
deaths by 80 % in the elderly [1]. WHO recommends an-
nual vaccination (in order of priority) for nursing-home
residents, elderly individuals, people with chronic medical
conditions and other high-risk groups, such as pregnant
women and children aged between 6 months to 5 years [1].
The European Union (EU) recommends that the national
vaccination committees follow the definition of risk groups
and “older age groups” as recommended by the European
Centre for Disease Prevention and Control (ECDC) [9]. In
contrast, the Centers for Disease Control and Prevention
(CDC) in US recommends influenza vaccination to the
general population over 6 months [10]. Currently, the
German Standing Committee on Vaccination (STIKO)
recommends annual influenza vaccination for high-risk
individuals, particularly those above 60 years of age and
pregnant women, in order to lower the disease burden
associated with seasonal influenza [11].
Healthy working adults traditionally have not been in-
cluded in the recommendations for influenza vaccination.
In 1996, the economic burden induced by productivitylosses as the result of seasonal influenza in Germany was
estimated to be €2.3 billion (DM 4.4 billion) [3]. However,
these values might now be higher and published data on
the current economic burden of influenza and the costs
per influenza episode in Germany are lacking.
The current retrospective database analysis aims to fill
the research gap, which has existed in Germany for over
10 years, by describing and quantifying the economic bur-
den associated with seasonal influenza in children and
adults at the primary care level.
Methods
Study design
This was a retrospective cost-of-illness analysis, using data
from a longitudinal electronic medical records (EMR) data-
base (IMS Disease Analyzer (DA)) in Germany to estimate
the cost per influenza or influenza-like illness (ILI) episode.
Direct cost for physician visits including referrals to special-
ists, drugs and hospitalizations were considered from payer
perspective and co-payments as well as transportation ex-
penses from patient’s perspective. Indirect cost due to work
days lost was taken from societal perspective into account.
Subsequently, the economic burden of influenza was ex-
trapolated for the whole of Germany by applying the de-
rived cost per episode to independently published estimates
of influenza-associated excess physician consultations per
season thereby considering influenza seasons of the last
10 years.
Database
The IMS DA comprises longitudinal patient-level data from
the physician-practice data systems (EMR) of office-based
physicians. The IMS DA Germany captures data from a
representative sample of 3,002 unique physicians, 2,357
unique practices and includes 15.5 million patient records.
The current retrospective database analysis was based on
the data from office-based primary care physicians (PCP
panel) and pediatricians (pediatricians panel) of IMS DA
Germany and covered 1,409 PCPs (i.e. 2.3 % of the 60,800
PCPs) and 221 pediatricians (i.e. 3.6 % of the 6,100
office-based pediatricians) across Germany. Compari-
sons with external data sources (e.g. data from Statutory
Health Insurance (SHI)) have underlined the validity
and representativeness of using the German IMS DA in
pharmacoepidemiological and pharmacoeconomic stud-
ies [12].
Population and episode
The population of this cost study consisted of patients with
influenza or ILI episodes, diagnosed using ICD-10 J09-J11
(International Classification of Diseases, 10th revision) dur-
ing the selection window from May 2010 to April 2012.
This population allowed the description of influenza and
Table 1 Demographic and clinical characteristicsa - patients







Gender female % (n) 55.3 (11,629) 47.2 (3,353)
Age in years
Mean ± SD 45.8 ± 17.8 6.9 ± 3.6
Min - Max 17.0–101.8 1.1–16.0
Age groups % (n)
<5 years 0.0 (0) 33.7 (2,394)
5–16 years 0.0 (0) 66.3 (4,713)
17–59 years 79.2 (16,666) 0.0 (0)
≥60 years 20.8 (4,373) 0.0 (0)
Insurance status at index date % (n)
Statutory Health Insurance 93.9 (19,765) 92.2 (6,550)
Private insurance 6.1 (1,274) 7.8 (557)
Relevant pre-period risk factorsb,c
(as defined by STIKO)
Weakened immune system
Cancer treatment (C00-C97) 1.9 (392) 0.1 (9)
HIV/AIDS (B20-B24) 0.1 (24) 0 (0)
Chronic illness
Any chronic disorders of respiratory
organs (J45, J46, J44, J38, J35)
9.5 (1,995) 22.9 (1,629)
Any cardiovascular disorders (I10-15,
I20-25, I26-I28, I30-I52, Z99.0-Z99.1)
28.5 (6,003) 0.8 (55)
Any cerebrovascular disorders
(I60-I69, G45)
1.9 (397) 0.1 (5)
Diabetes and other metabolic
diseases (E10-E14)
8.9 (1,876) 0.1 (7)
Hepatic disorders (B15-B19, K70, K75) 0.5 (114) 0.1 (6)
Renal disorders (N17- N19, Z99.2) 0.1 (196) <0.1 (1)
Any neurological disorders (G04-G05,
G20-G21,G30, G35, G40-G41)
1.4 (292) 0.8 (57)
Proportion of episodes with at least
one of the above mentioned pre-period
risk factors plus age ≥60 years in the
adult patient group % (n)
38.8 (8,165) 24.3 (1,727)
aAnalysis at episode level; bPre-period: 15–365 days before the index-date of
the episode; cRelevant diagnoses were documented as complications/severe
symptoms of influenza if they occurred within 14 days before or after the
index date. Equivalent diagnoses which could be both risk factors and
complications were unified within the “risk factor” term and documented as
such if they were made within 365 days before the index date.
HIV/AIDS Human immunodeficiency virus/acquired immune deficiency
syndrome, ILI Influenza-like illness, SD Standard Deviation, STIKO German
Standing Committee on Vaccination
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period from an epidemiological viewpoint.
In order to evaluate risk factors, complications and severe
symptoms as well as resource use associated with an influ-
enza or ILI episode, the following additional inclusion cri-
terion was applied: patients were continuously observable
in the database for at least 12 months before and at least
1 month after the diagnosis (index) date of the episode.
Notably, the 12-month observation period to diagnosis
(pre-index period) was used to define patient’s risk status.
An influenza or ILI episode was defined as the day of
physician visit when the index diagnosis was made (index
date), together with a related period of 14 days before and
14 days after that date. In order to distinguish between
two subsequent episodes in a single patient, a period of at
least 29 days between index dates was required. Complica-
tions and severe symptoms (according to the ICD-10
codes, please refer to Tables 1 and 2) were associated to
an influenza or ILI episode in the case they were re-
ported at index date or within 14 days before or after
the index date.
Information on influenza vaccination was not analysed
because documentation in the EMR data is ambiguous.
In practice, the influenza vaccine is often removed from
stock without specific prescription and the documented
diagnosis ICD-10 Z25.2, although indicating a need for
influenza vaccination, does not clearly ensure that the
vaccination was administered.
Analyses
Analyses were conducted at the episode level and
therefore included patients with one or more influenza
episodes. Data from the PCP and pediatrician panels
(patients’ age ≥17 years and 0–16 years, respectively)
were evaluated separately.
Number of influenza episodes
The number of influenza or ILI episodes was analysed per
month over the complete 24-month observation period.
Demographic and clinical characteristics
Socio-demographic characteristics were presented by pa-
tient’s age, gender and insurance status. The clinical risk
factors were described during the 365 days before the index
date of the episode and were defined according to STIKO.
The ICD-10 codes for underlying diseases are listed in
Table 1. Patients were considered “at risk” if they had at
least one of the diagnoses mentioned in Table 1 or were
≥60 years.
Relevant complications were identified according to pub-
lished literature [13, 14]. In addition, as the occurrence of
influenza-specific symptoms (for example, bronchitis and
pharyngitis) has an impact on the course of the illness and
associated costs, these symptoms were also considered incase they were recorded during the influenza and ILI epi-
sode (defined as diagnosis ICD-10 J09-J11, index date
±14 days). Complications and severe symptoms of an in-
fluenza infection were not explicitly discriminated in
this cost analysis. From a health economic perspective, the
Table 2 Occurrence (% (n)) and type of complications and
symptoms (by ICD-10 code)a,b - patients with influenza episodes






Bronchitis (J20-J22, J40-J44) 16.0 (3,368) 18.9 (1,346)
Acute upper respiratory (J06) 14.6 (3,063) 20.8 (1,479)
Sinusitis (J01, J32, J31) 6.0 (1,271) 8.9 (636)
Tonsillitis (J03) 2.4 (498) 7.8 (556)
Laryngitis (J04-J05) 2.3 (491) 4.2 (295)
Pneumonia (J12-J18) 1.6 (336) 5.4 (381)
Ear infection (otitis) (H65-H67) 0.9 (190) 13.4 (955)
Bronchiectasis (J47) 0 (0) 0 (0)
Cardiovascular disorders
(I30, I32, I33, I40, I42, I20-I24)
0.2 (52) 0 (0)
Cerebrovascular disorders (I60-I66) 0.1 (22) 0 (0)
Neurological disorders (G00-G05) <0.1 (6) 0.1 (5)
aAnalysis at episode level; bRelevant diagnoses were documented as
complications/severe symptoms of influenza if they occurred within 14 days
before or after the index date. Equivalent diagnoses which could be both risk
factors and complications were unified within the “risk factor” term and
documented as such if they were made within 365 days before the index date.
ICD International Classification of Diseases
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toms is not relevant for the calculation of episode-related
cost. Therefore, complications and severe symptoms are
summarized in the “Discussion” section under the term
“complication”. The relevant diagnoses are listed in
Table 2.
Relevant diagnoses were documented as complications/
severe symptoms of influenza if they occurred within
14 days before or after the index date. Diagnoses which
could be both risk factors and complications were unified
within the “risk factor” term and documented as such if
they were made within 365 days before the index date.
Resource and cost analysis
Resource consumption, due to the symptoms and
complications during influenza or ILI episodes (index
date ±14 days), was derived from data on physician
visits, referrals to other specialists (cardiologists, pneumol-
ogists, neurologists, otorhinolaryngologists, laboratory and
radiology, and others), drug prescriptions, hospital refer-
rals and sick notes available in the data source. Only
resource use and sick notes connected with influenza
(ICD-10 J09-J11) or complications and symptoms of influ-
enza were considered for the analysis. As no information
was available on sick notes for caregivers or the use of
over-the-counter (OTC) drugs in the database, these pa-
rameters were not considered in the analysis.
Direct costs from the payer perspective include cost of
physician visits, referrals to other specialists, hospitaladmissions with relevant diagnoses and cost of drugs for
treatment of influenza or its complications and symptoms.
Direct costs from patient perspective included patient’s ex-
penses for transportation and co-payment for drugs. The
cost of additional physician visits per episode, which were
not covered by the budget-per-quarter reimbursed by the
payers, was considered as direct cost from the societal
perspective.
The analysis of direct costs was based on resource
utilization data, expressed as the number of services used.
Cost was reported as the number of consumed services
combined with the unit cost of each resource. The num-
ber of resources consumed was multiplied by the specific
unit cost for each service. Published unit costs and tariffs
from 2012 were used as follows: official medical fee sched-
ule (Einheitlicher Bewertungsmaßstab (EBM)) 2012 for
office-based physician visits; the German Diagnosis-
Related Groups (G-DRG) Catalogue 2012 plus base rate
in 2012 (€2,992) provided by the National Association
of Statutory Health Insurance Funds for inpatient stays;
the German Rote Liste 2012 for drugs [15–18] (see
Additional file 1 for details). For the calculation of drug
cost, the price per prescribed package was considered.
Analysis of drug co-payments was performed for patients
aged 18 years and above. Patient and family expenses for
transportation were calculated based on the number of
physician visits multiplied by patient expenses as de-
scribed in the published literature [19].
For the calculation of indirect costs, the number of days
absent from work was multiplied with the average product-
ivity loss per day. The IMS DA provides information on the
number of days recommended to be absent from work
recorded on the sickness notes. The monetary value of
productivity loss per day for employed persons was calcu-
lated based on gross wage data and the number of persons
in dependent employment (data source: German Federal
Statistical Office 2012 [20]) in accordance with German
recommendations on health economic evaluation 2008
[21].
The time horizon for cost analysis per episode was 29 days
(index date ±14 days). The complete influenza-related re-
source use and sick leave starting during the episode were
considered for cost analysis. No censoring at day 14 after the
index date was undertaken. The results of the cost analysis
were stratified according to age and the presence of risk fac-
tors or complications and severe symptoms. Discounting of
costs was not applied.
Estimation of the annual economic burden of physician-
attended influenza
The annual economic burden was estimated by multiplying
cost per episode, derived from the current analysis, with
the number of influenza-associated excess consultations
per influenza season published by The Robert Koch
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describe the seasonal variation of medically attended acute
respiratory infections and the estimation of their excess, at-
tributable to influenza, based on virological data from senti-
nel practices around Germany. A detailed description of
the model was published by an der Heiden et al. in 2013
[23].
The minimum and maximum numbers of excess consul-
tations for children and adults used for the extrapolation
was based on the figures available for the last 10-year influ-
enza seasons (2005–2014) in Germany.Statistics
All analyses were conducted using descriptive statistical
methods. Total number, number of missing values, mini-
mum, median, maximum, mean, standard deviation (SD)
and the lower and upper limit of 95 % confidence intervals
(CI) for the mean were provided for continuous variables.
For categorical parameters, the absolute and relative fre-
quencies were reported. The available information was ana-
lyzed “as reported” and missing values were not replaced.
Data were analyzed using SAS version 9.2.Results
Between May 2010 and April 2012, 42,822 episodes in
37,471 patients ≥17 years were identified in the PCP
panel and 12,295 episodes in 11,049 patients <17 years
were identified in the pediatricians panel. The vast ma-
jority of episodes (PCP panel: 96.4 %, pediatricians panel:
92.7 %) was classified as ICD-10 J11 “influenza, virus not
identified”. The remaining episodes were classified as
ICD-10 J9 “Influenza due to certain identified influenza
virus” (PCP panel: 0.8 %, pediatricians panel: 4.0 %) or
ICD-10 J10 “Influenza due to other identified influenza
virus” (PCP panel: 2.8 %, pediatricians panel: 3.3 %). For
the majority of patients, the diagnosis was made based on
clinical symptoms and was not confirmed by laboratory
tests.
The peak of influenza episodes for the season 2010/
2011 was observed in February 2011 and in March 2012
for the season 2011/2012 (Fig. 1).Population for analysis
A total of 21,039 influenza episodes in 17,836 adults man-
aged by PCPs and 7,107 episodes in 6,288 children managed
by pediatricians were eligible for the analysis of clinical char-
acteristics, resource use and cost according to the inclusion
criterion.
The vast majority of patients had one influenza episode
(adults: 87.2 %, children: 90.0 %) or two influenza episodes
(adults: 9.9 %, children: 7.9 %) within the 24-month observa-
tion period.Demographic and clinical characteristics
The demographic and clinical characteristics are sum-
marized in Table 1.
The mean (±SD) age of patients was 45.8 (±17.8) years in
the PCP panel and 6.9 (±3.6) years in the pediatricians panel.
The majority of patients, 93.9 % and 92.2 % respectively, was
insured by SHI.
The presence of clinical risk factors was documented for
38.8 % episodes in adults (including age ≥60 years) and
24.3 % episodes in children. The most common clinical risk
factors were cardiovascular diseases in adults (28.5 %) and
respiratory diseases in children (22.9 %).
Complications and symptoms
Complications and severe symptoms frequently accom-
panying influenza episodes are presented in Table 2. Com-
plications and severe symptoms accompanied the
influenza-attributable episode in 37.4 % of adults and in
53.7 % of children. Bronchitis (adults: 16.0 %, children:
18.9 %) and acute upper respiratory infections (adults:
14.6 %, children: 20.8 %) were the most common symp-
toms. In adults, sinusitis (6.0 %) and in children, ear
infections (13.4 %) and sinusitis (8.9 %) were the most fre-
quent complications. Pneumonia was recorded in 1.6 % of
adults and 5.4 % of children. At least one of these condi-
tions was reported during the majority of episodes in pa-
tients without risk factors (adults: 55.8 %; children:
70.9 %).
Resource use and cost
The mean (±SD) number of physician visits was 1.2 (±0.5)
per episode in adults and 1.5 (±0.8) per episode in children.
Referrals to other specialists were recorded during 13.6 %
episodes in adults and 7.4 % episodes in children. The per-
centage of patients hospitalized because of influenza or its
complications was similar in the PCP and pediatricians
panels, 0.7 and 0.9 % respectively. Drug prescriptions relat-
ing to either the influenza diagnosis or complications/se-
vere symptoms were issued during 48.1 % episodes in
adults and 55.1 % episodes in children (Table 3). The mean
(±SD) number of drug classes prescribed was 0.8 (±1.0)
per episode in adults and 1.0 (±1.1) per episode in chil-
dren. In adults, the most frequently prescribed drug
class was expectorants (25.7 % episodes) followed by an-
algesics (20.1 % episodes) and macrolides (15.9 % epi-
sodes). In children, the most frequently prescribed drug
class was analgesics (46.7 % episodes) followed by
expectorants (33.0 % episodes) and nasal decongestants
(32.1 % episodes).
Sickness certificates were issued during 60.7 % episodes
in adults (12,779 of 21,039 episodes) and in <0.1 % epi-
sodes in children (3 of 7,107 episodes). Adults missed up
to 6 days from work during 46.7 % episodes; 7 or more
days were missed during 14.0 % episodes. The overall
Fig. 1 Number of influenza/ILI episodes per month reported in the primary care physicians (PCP) and the pediatricians panels between May 2010
and April 2012 in Germany
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days in adults.
The mean (±SD) total cost per episode, from a societal
perspective, was €514 (±609) in adults and €105 (±224)
in children (Table 4). The total cost per individual epi-
sode exceeded €1,000 in about 12.6 % episodes in adults.
The main cost driver in adults is indirect cost (82 %)
followed by direct cost from payer perspective.
Stratified by age group, the mean (±SD) total cost in
adults was higher in patients between 17 and 59 years
(€584 (±608)) and was considerably lower in patients
≥60 years (€248 (±535)). In children, the total costs were
more comparable in all age groups, ranging from €96
(±214) in children aged 5–16 years to €124 (±242) in chil-
dren younger than 5 years of age (Fig. 2).
Complications and severe symptoms increased the
mean (±SD) total cost per episode 1.7 times in adults
(€684 (±713) with complications or severe symptoms vs.
€413 (±510) without) and nearly 3 times in children
(€149 (±278) vs. €55 (±116)) (Fig. 3).
Annual economic burden of physician-attended influenza
Based on the last 10 annual influenza seasons in Germany,
excess consultations per season ranged from 0.2 to 2.2
million in children and from 0.3 to 5.6 million in adults.Multiplying the number of influenza-associated excess
consultations by total cost per episode of €105 (for chil-
dren) and €514 (for adults) results in an annual economic
burden of physician-attended seasonal influenza of €0.2–
€3.1 billion from societal perspective (Table 5).
Discussion
The current retrospective database analysis describes and
quantifies the burden of seasonal influenza in adults and
children at the primary care level in Germany. The aim of
the manuscript was to estimate the annual economic bur-
den of influenza in Germany. Due to the lack of up to date
cost data, we have assessed the resource consumption re-
lated to the treatment of episodes classified as influenza or
ILI (ICD-10 J9-J11) by primary care physicians. The aim
was not to evaluate the incidence of confirmed influenza
in Germany. Due to this reason, we have used figures pub-
lished by RKI to extrapolate the cost per episode to the
economic burden in Germany. Our analysis, based on a
very large sample of patients with clinically diagnosed
influenza, showed that the annual economic burden of
seasonal influenza can reach €3.1 billion. Interestingly, a
substantial burden occurs in adults without risk factors
for complications and thus outside the recommended
groups for seasonal influenza vaccination.
Table 3 Drug prescriptions related to influenza and
complications (%(n))a - patients with influenza episodes








Drug prescription no 51.9 (10,914) 44.9 (3,190)
Drug prescription yes 48.1 (10,125) 55.1 (3,917)
Prescribed drugs
Analgesics N02B1 9.9 (999) 0.3 (12)
N02B2 10.2 (1,031) 46.4 (1,817)
Antirheumatics
non-steroid, plain
M01A1 6.9 (699) 0.9 (36)
Nasal decongestants R01A7 3.8 (380) 32.1 (1,256)
Antitussives, plain R05D1 12.4 (1,251) 9.0 (352)
Cold preparations R05A0 7.9 (804) 0.6 (24)
Expectorants R05C0 25.7 (2,599) 33.0 (1,292)
Tetracyclines &
combinations
J01A0 5.0 (506) 0.2 (9)
Broad spectrum
pencillin oral
J01C1 6.5 (659) 5.9 (230)
Cephalosporins oral J01D1 5.5 (560) 9.9 (389)
Macrolides & similar type J01F0 15.9 (1,612) 6.7 (262)
Oral fluoroquinolones J01G1 6.7 (681) 0
Influenza antivirals J05B4 5.7 (575) 6.6 (260)
aAnalysis at episode level
ATC code Anatomical Therapeutic Chemical code, EphMRA European
Pharmaceutical Marketing Research Association
Table 4 Total cost per influenza/ILI episode (€)a - patients with epis
Adults
N episodes = 21,039
Mean (SD)
Physician visits 32 (2)
Referrals to other physicians 2 (9)
Hospital admissions with relevant diagnoses 14 (178)
Drug treatment 11 (51)
Subtotal - direct cost payer 59 (188)
Co-payments drugs 7 (12)
Transportation 8 (4)
Subtotal - direct cost patient 15 (15)
Physician visits 16 (24)
Subtotal - direct cost not covered by payer 16 (24)
Work days lost 424 (566)
Subtotal - indirect cost 424 (566)
Total cost from societal perspective 514 (609)
aAnalysis at episode level
SD Standard Deviation
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between May 2010 and April 2012 in Germany reveals
the monthly distribution of influenza/ILI episodes and
accurately describes the 2010/2011 and 2011/2012 influ-
enza seasons [24, 25]. In the season 2010/2011, the peak of
influenza episodes was observed between January and
March. In the following season (2011/2012), the peak oc-
curred between February and March. However, this was
much flatter compared to the 2010/2011 season. Our obser-
vations of monthly influenza/ILI episode distribution corres-
pond to the patterns in reportable positive influenza
diagnoses and practice consultations recorded by the RKI
acute respiratory disease (ARE) monitoring system.
Influenza episodes are frequently accompanied by com-
plications. We observed complications in 37.4 % of adults
and in 53.4 % of children. Three circumstances, however,
make it challenging to compare our findings with the pub-
lished literature. Firstly, results often refer only to hospital-
ized patients; secondly, the types of reported complications
differ; and thirdly, the time period patients are followed-up
for varies widely. In a retrospective US managed care data-
base analysis, complications were documented in 65 % of
adults within a 12-month follow-up period [4], as com-
pared to our findings in adults (37.4 %). The difference can
be explained by the large variation in length of follow-up
(12 months in the US analysis vs. 1 month in the present
analysis) and the range of investigated complications,
which was broader in the US analysis and included muscu-
loskeletal diseases, diabetes and infectious diseases in
addition to respiratory disorders. In the present analysis,
the most frequent complications in children managed by
pediatricians were respiratory tract infections (20.8 %) andodes between May 2010 and April 2012 in Germany
Children
N episodes = 7,107
Median (Min – Max) Mean (SD) Median (Min – Max)
31 (31–36) 35 (5) 31 (31–42)
0 (0–129) 1 (5) 0.0 (0–88)
0 (0–6,002) 17 (193) 0 (0–3,411)
0 (0–2,216) 13 (33) <1 (0–708)
35 (31–6,060) 66 (201) 42 (31–3,527)
0 (0–245) 0 (0) 0 (0–0)
6 (6–66) 9 (5) 6 (6–54)
12 (6–275) 9 (5) 6 (6–54)
0 (0–393) 30 (35) 31 (0–292)
0 (0–393) 30 (35) 31 (0–292)
385 (0–11,664) 1 (62) 0 (0–4,230)
385 (0–11,664) 1 (62) 0 (0–4,230)
421 (37–11,878) 105 (224) 72 (37–4,534)
Fig. 2 Total cost per influenza/ILI episode (€) stratified by age group in patients with episodes between May 2010 and April 2012 in Germany
(PCP: primary care physicians)
Ehlken et al. BMC Public Health  (2015) 15:578 Page 8 of 11otitis media (13.4 %); this pattern is comparable with pub-
lished literature [26, 27]. In a review of pediatric influenza
managed in the community and primary care in Western
Europe, frequent complications included otitis media (be-
tween 0 and 41 %), bronchitis (between 5 and 10 %), pha-
ryngitis (between 31 and 58 %) and the common cold
(between 15 and 20 %) [26].
Some conditions can put patients at higher risk for de-
veloping complications. Overall, we found the most fre-
quent risk factors for complications to be cardiovascular
diseases in adults (29 %) and respiratory diseases in chil-
dren (23 %). These are in line with common risk factors
reported in three independent meta-analyses [28–30].
The first meta-analysis revealed a double risk of develop-
ing severe influenza complications (odds ratio 1.97, 95 %
CI 1.06 – 3.67) when patients suffered from cardiovascu-
lar diseases compared to patients without [28]. In the
second meta-analysis, cardiovascular diseases accounted
for 17.2–20.0 % of all influenza-related hospitalizationsFig. 3 Total cost per influenza/ILI episode (€) stratified by complications (ye
Germany (PCP: primary care physicians)[29], and in the third meta-analysis, influenza vaccination
reduced the risk of severe complications by half (risk ratio
0.57, 95 % CI 0.39 – 0.82) [30]. The authors suggest that
in patients with cardiovascular diseases, influenza may
trigger the rupture of a vulnerable atherosclerotic plaque
and thus lead to severe complications [30].
From societal perspective, the cost per episode is sub-
stantial. According to the current analysis, mean total
costs in adults are about €514 per influenza episode and
about €105 in children. Overall, the annual economic
burden in Germany based on the present analysis of out-
patient EMR data corresponds to the cost dimension
published by Szucs et al. in 2001 [3].
The main cost driver in adults is indirect cost because
of work days lost. Our findings are in accordance with
the published literature [3, 5]. In adults with high cost
episodes (> €1,000), more patients (90 %) were of work-
ing age compared to the total group (79 %) managed by
PCPs. In the present analysis, the mean number of works/no) - patients with episodes between May 2010 and April 2012 in
Table 5 Estimated cost per influenza season [22]
Estimated number of excess consultations per age
group and season
Cost per age group and season in Billion € Estimated total cost per
season in Billion €
Season Age group Age group Age group Age group All age groups
0–14 years 15+ years 0–14 yearsa 15+ yearsb
2013/2014 220,000 550,000 0.023 0.283 0.306
2012/2013 2,150,000 5,560,000 0.226 2.858 3.084
2011/2012 530,000 1,600,000 0.056 0.822 0.878
2010/2011 810,000 1,320,000 0.085 0.678 0.763
2009/2010 1,070,000 1,870,000 0.112 0.961 1.073
2008/2009 1,335,000 2,925,000 0.140 1.503 1.643
2007/2008 500,000 705,000 0.053 0.362 0.415
2006/2007 1,285,000 1,435,000 0.135 0.738 0.873
2005/2006 550,000 310,000 0.058 0.159 0.217
2004/2005 2,210,000 3,240,000 0.232 1.665 1.897
anumber of excess consultations multiplied by € 105
bnumber of excess consultations multiplied by € 514
Ehlken et al. BMC Public Health  (2015) 15:578 Page 9 of 11days lost was 6.0 days in adults with recorded sick notes.
This range is consistent with previous publications where
3.7–5.9 work days per episode have been reported lost fol-
lowing physician diagnosis of influenza [31].
The costs of seasonal influenza episodes were higher
when patients were of working age and/or had experienced
influenza-related complications. In the present analysis, in-
fluenza episodes in the working age group (17–59 years)
were associated with mean total costs 2.4-times higher
than those in patients ≥60 years. Complications almost tri-
pled the cost per episode in children and increased the
costs by a factor of 1.7 in adults. These findings are in line
with results published by Karve et al. [4], where healthcare
costs among influenza patients with complications were
double those of influenza patients without complications.
In the present analysis, the majority of episodes with
complications were reported in patients without risk fac-
tors. Adults without risk factors have traditionally not
been included in influenza vaccination recommendations,
which include only nursing-home residents, elderly indi-
viduals, and people at high risk for complications [1]. Con-
sequently, a substantial burden occurs in patients outside
the recommended group for receiving seasonal influenza
vaccination. In Germany, healthy working adults have sea-
sonal vaccination coverage of less than 16 % [32, 33].
If vaccination rates in healthy working adults were in-
creased, the economic burden due to work days lost
could be reduced substantially [34]. Based on a review of
economic evaluations of seasonal influenza vaccination
in healthy working age adults in the US, the authors
conclude that vaccination does not generally save costs,
but may be economically attractive under certain condi-
tions, such as higher illness rates, lower costs of vaccin-
ation and higher wage rates [35]. To assess, whether
vaccination is cost saving for a certain country, anevaluation based on country-specific epidemiological
and health economic data is necessary.
In Germany, influenza vaccine recommendations for
adults should be revisited in the future. The analysis of
influenza surveillance by RKI during the 2012/2013 sea-
son showed that absence from work due to influenza
reached the highest value for the last 10 years; there were
more than 4 million reports of absenteeism [36]. Vaccin-
ation in children is widely discussed among clinicians [37]
and a recent literature review concluded that vaccination
in children, especially those below 5 years, reduces the
influenza-associated disease burden [27]. Such reports
emphasize the importance of targeting children and adults
in national immunization policies.
There are limitations to the interpretation of our re-
sults. Overall, it has to be considered that the realization
of the actual costs of seasonal influenza is challenged by
the fact that the disease is underreported [38]. On the
other hand, with respect to the cost per episode analysed
in the present database analysis, the vast majority of epi-
sodes (over 92 %) was classified as “influenza, virus not
identified” (ICD-10 J11). As the aim of the analysis was
to describe the current economic burden, we did also
consider the ICD-10 J11 diagnosis when describing the
cost per influenza or ILI episode. Potentially, this intro-
duces an underestimation of total costs, because ILI epi-
sodes might come with a milder course of the disease
with shorter absence from work. Secondly, the total cost
per episode is very likely to be underestimated because
of missing information on emergency visits and admis-
sions at hospitals in the IMS DA database, which is based
on EMR data at office-based practices and not linked to
hospital records. Also, information on patient expenses
for OTC medication was not available in the EMR data.
Thirdly, an underreporting of parental sick leaves is very
Ehlken et al. BMC Public Health  (2015) 15:578 Page 10 of 11probable. In children, sick certificates were recorded only
for 3 episodes in the current analysis. According to a lit-
erature review in Western European countries, parental
absenteeism is common (11–62 %) and lasts on average
from 1.3 to 6.3 days in the parents of children with
laboratory-confirmed influenza [26]. Additionally, co-
payments were considered for all adult patients and
without taking into account patient groups who do not
have to co-pay, like those on chronic medication or un-
employed. This results in a possible slight overestimation
of co-payments. Finally, the extrapolation of cost per epi-
sode to annual economic burden of physician-attended in-
fluenza in Germany is a conservative calculation, because
it was based on practice consultations and not on inci-
dence figures. Therefore, an annual economic burden of
up to €3.1 billion could be greatly underestimated.Conclusion
Findings demonstrate that in Germany, seasonal influ-
enza is associated with a substantial clinical and eco-
nomic burden. The current analysis provides an update
of the economic burden associated with influenza and
ILI in Germany based on a large patient sample derived
from a representative primary care physicians’ panel.
Nevertheless, the economic burden of influenza in
Germany remains underestimated where influenza is
underreported and comprehensive information on
hospitalization and death related to influenza is not sys-
tematically recorded. Improving the effectiveness or
coverage of influenza vaccination has the potential to re-
duce the burden of influenza.Additional file
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